ICMRA high-level meeting on global health emergencies and regulatory approaches

6 December 2021 - On 1 - 2 December, International Coalition of Medicines Regulatory Authorities, a group of leading medicines regulatory ...

Read more →

Product approval and public health at the US Food and Drug Administration

6 December 2021 - Since the 1962 Kefauver-Harris Amendments to the Federal Food, Drug, and Cosmetic Act, drug approval in ...

Read more →

Theratechnologies submits supplemental biologics license application to FDA advancing development of IV push Trogarzo for patients living with HIV

6 December 2021 - sBLA submission with FDA follows on the back of recently announced positive TMB-302 study results. ...

Read more →

Sapience Therapeutics receives FDA fast track designation for ST101 for the treatment of recurrent glioblastoma multiforme

6 December 2021 -  Sapience Therapeutics announced today that the U.S. FDA has granted fast track designation to its lead ...

Read more →

EMA recommends approval for use of RoActemra in adults with severe COVID-19

6 December 2021 - The EMA’s CHMP has recommended extending the indication of RoActemra (tocilizumab) to include the treatment of ...

Read more →

TGA provisional approval of Celltrion COVID-19 treatment regdanvimab (Regkirona)

6 December 2021 - On 6 December 2021, the TGA granted provisional approval to Celltrion Healthcare for the use of ...

Read more →

Secura Bio announces Copiktra (duvelisib) strategic focus on T-cell lymphoma and voluntary U.S. withdrawal of the relapsed or refractory follicular lymphoma indication

3 December 2021 - Secura Bio has voluntarily withdrawn the U.S. Copiktra indication for the treatment of patients with relapsed or ...

Read more →

Chiesi Global Rare Diseases announces updated U.S. Prescribing Information for Ferriprox (deferiprone)

3 December 2021 - Chiesi Global Rare Diseases announced today that the Ferriprox (deferiprone) Prescribing Information in the U.S. has been ...

Read more →

RefleXion receives breakthrough device designation for lung cancer treatment

1 December 2021 - RefleXion Medical today announced that the U.S. FDA has granted the company breakthrough device designation for ...

Read more →

FDA approves new Kyprolis (carfilzomib) combination regimen with Darzalex Faspro (daratumumab and hyaluronidase-fihj) and dexamethasone for patients with multiple myeloma at first or subsequent relapse

1 December 2021 - Kyprolis in combination with subcutaneous treatment regimen provides further options and convenience for patients with relapsed/refractory ...

Read more →

Pfizer's COVID-19 vaccine (Comirnaty) provisionally approved for use in individuals 5 years and over

5 December 2021 - The TGA has provisionally approved the Pfizer COVID-19 vaccine, Comirnaty, for use in individuals 5 years ...

Read more →

Janssen seeks approval of Imbruvica (ibrutinib) in a fixed duration regimen for patients with untreated chronic lymphocytic leukaemia

30 November 2021 - Application based on Phase 3 GLOW and Phase 2 CAPTIVATE study results, which investigated the safety ...

Read more →

U.S. Food and Drug Administration accepts for priority review supplemental biologics license application for Reblozyl (luspatercept-aamt) in adults with non-transfusion dependent beta thalassaemia

3 December 2021 - Submission based on results from Phase 2 BEYOND study of Reblozyl plus best supportive care in ...

Read more →

European Medicines Agency validates Amicus Therapeutics marketing authorisation applications for AT-GAA for the treatment of Pompe disease

3 December 2021 - Amicus Therapeutics today announced that the EMA validated the marketing authorisation applications for AT-GAA, the Company’s ...

Read more →

Reforms needed for FDA’s regulation of medical devices

3 December 2021 - Medical devices are mainstays of modern medicine, from basic products like gloves and bandages to complex ...

Read more →